Chronic Drug-Induced Liver Injury Can Be Safer
This newspaper, Beijing, February 16 (Reporter Tian Yating, Correspondents Wang Chunyan and Dai Xin)
Chronic drug-induced liver injury is one of the most common clinical drug-induced diseases and the most concerned drug-induced diseases in the world.
A few days ago, the Department of Liver Diseases of the Fifth Medical Center of the PLA General Hospital made a breakthrough in the research of chronic drug-induced liver injury, and established a prediction model for the delayed recovery of chronic drug-induced liver injury for the first time in the world. Pharmacovigilance provides objectively quantifiable means.
The research results have been published online in Hepatology, the top international journal in the field of liver disease.
It is understood that there are more than 1,100 listed drugs in the world with potential liver toxicity, including chemical drugs, biological preparations, traditional medicines, health products, dietary supplements, etc.
Although most patients with chronic drug-induced liver injury can obtain biochemical remission after discontinuing suspicious drugs, 8% to 20% of patients still develop chronic drug-induced liver injury, and repeated episodes of the disease may progress to liver cirrhosis or even liver failure. It causes a great psychological and economic burden to patients and their families.
Therefore, finding and identifying high-risk factors affecting the delayed recovery (BNR) of chronic drug-induced liver injury, thereby improving the treatment efficiency of chronic drug-induced liver injury, has become a key issue to be solved in clinical research.
Therefore, Ji Dong, Zou Zhengsheng and Xiao Xiaohe team from the Department of Liver Diseases of the Fifth Medical Center of the PLA General Hospital jointly tackled key problems. Through a multi-center retrospective study of 5326 patients with chronic drug-induced liver injury in 9 hospitals across the country, the important factors affecting BNR were revealed. factor.
The research team has also innovatively established a nomogram model that can be used to predict the delayed recovery of drug-induced liver injury, and named it BNR-6, which can provide accurate stratified management and risk early warning for patients with chronic drug-induced liver injury. powerful tool.
Clinical applications show that the BNR-6 model is highly consistent with liver histology, allowing individualized calculation of BNR risk for each patient.
When the BNR-6 score is significantly high, it predicts that patients with chronic drug-induced liver injury have a high risk of delayed recovery, and should be treated more aggressively and followed closely; when the BNR-6 score is significantly low, the risk of BNR is considered low, and follow-up can be appropriately reduced times, saving medical expenses.
It is reported that with the help of the BNR-6 model, patients with chronic drug-induced liver injury can be accurately distinguished, avoiding the possible damage to the liver of patients by needle biopsy, and it is easy to implement, which can be widely used in clinical diagnosis and treatment of liver diseases and safe drug use.